Thumbnail for website
Press Releases

VolitionRx Highlights a Transformational Year: Clinical Validation, Commercial Partnerships, and Potential Upcoming Milestones

November 17, 2026

Peer-reviewed validation in sepsis, >95% early-stage cancer detection in a blinded cohort, a government-funded sepsis program in France, licensing discussions with more than a dozen diagnostic companies worldwide, an expanded Fujifilm agreement to include cats, and over $5 million of debt reduction

HENDERSON, Nev., November 17, 2026 /PRNewswire/ — VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company, today highlights the progress it has made across its Nu.Q® platform in 2026. Volition now has wide-ranging clinical evidence, partner programs and licensing discussions in place across its key product pillars, each targeting multi-billion-dollar markets.

2026 Key Milestones

  • Volition is in discussions with more than a dozen of the world’s leading diagnostic and liquid biopsy companies to licence its proprietary platform protected by over 70 patents.
  • Volition’s model is to co-develop with third parties and license its technology for upfront and milestone payments, royalties and other recurring revenue, while keeping its own costs low.

Nu.Q® NETs: Sepsis and NETosis

  • Landmark peer-reviewed validation: Critical Care Medicine published data, with an accompanying editorial, showing Nu.Q® NETs H3.1 independently predicts 28-day mortality and need for kidney replacement therapy in sepsis and septic shock.
  • Sole biomarker in France’s DETECSEPS program: launched in September, this €6.3 million (~$7.3 million) government-funded program is evaluating Nu.Q® NETs in emergency departments potentially to become part of the national screening test for Sepsis.
  • Finger-prick test: Volition’s rapid lateral flow prototype showed high correlation with its CE-marked automated assay in ICU sepsis patients, opening the door to testing outside central laboratories. LOI with Missionpharma to develop and launch worldwide.
  • New indications: a Mayo Clinic study of 674 trauma patients demonstrated that nucleosome levels, as measured by Volition’s Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people that have experienced a traumatic event, and are even higher in those patients that go on to have complications from the trauma. H3.1 levels in healthy people were 22.3 ng/ml, those with trauma were 359.7 and those that went on to get Venous Thromboembolism (VTE) were 828.4, over 37 times the level in healthy subjects. In our view, an ability to predict VTE (blood clots) in trauma patients with a simple blood test could be extremely clinically useful.

Nu.Q® Cancer and Capture-Seq™

  • >95% of early-stage cancers detected: in a blinded validation cohort of 81 subjects (colorectal and lung cancer patients and healthy controls), Capture-Seq™ detected 94% of stage I and 96% of stage II cancers, with 93% overall sensitivity at 95% specificity.
  • First peer-reviewed Capture-Seq™ paper published in August; early stage I detection data presented at the ESMO MAP conference in September.
  • Lung cancer: new prognostic and risk-stratification data; reimbursement submission for Nu.Q® Lung Cancer in France being prepared with Hospices Civils de Lyon, expected to be submitted this quarter.

Nu.Q® Vet

  • Third species: the feline prototype detected 86% of feline lymphomas at 97% specificity; the manuscript is in peer review and publication is expected to subsequently unlock a $5 million milestone payment.
  • Fujifilm agreement expanded to include cats: in November, Volition expanded its supply agreement with Fujifilm Vet Systems in Japan to allow the development and use of the Nu.Q® Vet Feline Test, extending the potential use of Nu.Q® technology to Japan’s almost nine million cats. Volition expects this to be the world’s first simple, affordable blood-based liquid biopsy test for feline cancer.
  • First automated Nu.Q® Vet Cancer Test launched with Fujifilm Vet Systems for dogs.

A Stronger Financial Position

  • Revenue growth: year-to-date revenue through September 30, 2026, of $3.0 million, up 134% on the first nine months of 2025.
  • Lower costs: year-to-date operating costs down 13% and operating loss down 24%.
  • Convertible note debt reduced by over $5.0 million since June 30, 2026. Remaining convertible note principal is approximately $0.7 million.

What Comes Next

Upcoming potential milestones include:

  • Publication of the feline manuscript anticipated subsequently to unlock $5 million milestone payment;
  • Further licensing, and co-development agreements across multiple pillars;
  • Broader agreements with some of our current NETs licencing partners, which currently include Sysmex and, Werfen;
  • Submission of the Nu.Q® Lung Cancer reimbursement application in France;
  • Advancement of the DETECSEPS program;
  • Routine use in a clinical setting in Europe of the Nu.Q® NETs test;
  • Moving to a definitive agreement with Missionpharma, with which Volition signed a non-binding Letter of Intent in October for its finger-prick sepsis test.

Cameron Reynolds, President and Group Chief Executive Officer, said:

“2026 has been a year of validation and progress. Independent peer-reviewed data now support Nu.Q® across sepsis and NETosis, cancer and animal health, which is driving our licencing discussions worldwide with a range of very large companies. Each of our key pillars targets a multi-billion-dollar market, and we only need a few of these agreements to be finalised to transform Volition commercially. At the same time, we have cut costs and substantially reduced our debt. Our focus now is converting this progress into more signed agreements.”

 

Volition